Sector News

Medivation working with JPMorgan on takeover approaches: sources

April 4, 2016
Life sciences

Medivation Inc has been working with investment bank JPMorgan Chase & Co to handle interest from other companies in a potential acquisition, but it has no plans to sell itself, according to people familiar with the matter.

The move is not uncommon in the healthcare industry. Biopharmaceutical companies such as Medivation are often approached by larger industry players. But acquisitions rarely happen without the target company cooperating.

Some of the approaches have taken place since the start of the year, the people said, without disclosing the names of the interested parties. The sources asked not to be identified because the matter is confidential.

Medivation did not immediately respond to a request for comment, while JPMorgan declined to comment.

Based in San Francisco, Medivation focuses on drugs for treating cancer. It has a market capitalization of $6.1 billion.

Sanofi SA, Roche Holding AG and AstraZeneca Plc are among the pharmaceutical companies that have expressed interest in acquiring drug makers in the United States.

Medivation has been under pressure from lawmakers, including Democratic Party presidential hopeful Bernie Sanders, a U.S. senator of Vermont, who criticized the high price of its only approved drug, Xtandi, which treats prostate cancer.

Beyond Xtandi, Medivation has a number of other potential cancer treatments in advanced stages of research and development.

The company’s stock has traded down more than 40 percent in the past year, in tandem with a broader selloff in the life sciences sector.

Earlier this week, Medivation hired Jennifer Jarrett as its new chief financial officer. She will replace Rick Bierly, who will retire in July.

By Carl O’Donnell and Greg Roumeliotis in New York

Source: Reuters

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”